SPEAKER: Jianfeng Xu, MD, DrPH | Vice President of Translational Research, Director of the Program for Personalized Cancer Care, and The Ellrodt-Schweighauser Family Chair of Cancer Genomic Research, NorthShore University HealthSystem; and Research Professor, Pritzker School of Medicine, University of Chicago
“Inherited Risk Assessment of Cancer and Other Common Diseases in Clinic: It Takes Three to Do It Right”
Wednesday, Feb. 19, 2020 | 4 - 5 p.m. | COM-T Room 5403
- Refreshments Available after 3:45 p.m. -
– CME CREDIT AVAILABLE –
About the Presenter:
Jianfeng Xu, MD, DrPH, is a genomic translational researcher. He was trained in medicine, public health, and genetic epidemiology at Shanghai Medical University, in China, and the Johns Hopkins University School of Public Health in Baltimore, Maryland. Dr. Xu’s primary research interests are: 1) discovery of genes that are associated with development and progression of diseases, and 2) translationof genomic findings for targeted prevention, screening, and treatment of diseases.
He and his colleagues discovered multiple genes for cancer and other diseases and have published over 430 papers in high impact journals including the New England Journal of Medicine, Nature Genetics, JAMA, Lancet, and Science.
Dr. Xu developed a genetic risk score (GRS) to measure the cumulative effect of multiple risk-associated variants on disease risk. Since published the GRS method and its application in prostate cancer 10 years ago, he has been working continuously and persistently to improve the GRS method and implement it in clinic.
gggr.jianfeng.xu_.m.d.pr_.ph_.flier_.2-19-20.pdf